STN: 125285
Proper Name: Influenza Vaccine
Tradename: Flublok Quadrivalent
Manufacturer: Protein Sciences Corporation
Indication:
- For active immunization against disease caused by influenza A subtype viruses and influenza type B viruses contained in the vaccine. Flublok Quadrivalent is approved for use in persons 18 years of age and older.
Product Information
Supporting Documents
- March 19, 2025 Clinical Review Memo – Flublok Quadrivalent
- Statistical Review – Flublok Quadrivalent & Flublok
- June 30, 2023 Approval Letter – Flublok Quadrivalent
- July 1, 2022 Approval Letter – Flublok Quadrivalent
- May 11, 2022 Approval Letter – Flublok Quadrivalent
- July 2, 2021 Approval Letter – Flublok
- July 2, 2020 Approval Letter – Flublok
- May 12, 2020 Approval Letter – Flublok
- July 2, 2019 Approval Letter – Flublok
- April 15, 2019 Approval Letter – Flublok Quadrivalent
- June 29, 2018 Approval Letter – Flublok Quadrivalent
- April 4, 2018 Approval Letter – Flublok Quadrivalent
- July 7, 2017 Approval Letter – Flublok Quadrivalent
- Statistical Review – Flublok Quadrivalent
- Clinical Review – Flublok Quadrivalent
- Supporting Documents older than three years – Flublok Quadrivalent
-
Content current as of:
05/22/2025
